Clinical trial
Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
NCT07863765 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Multi-Center Open-Label Trial of Enfortumab Vedotin Treatment for Patients With Aggressive Radioiodine Refractory Differentiated Thyroid Cancer, Aggressive Poorly Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer and NUT Carcinoma
- Lead sponsor
- Northwestern University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 5, 2027
- Completion date
- May 5, 2031
- Enrollment
- 56 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic differentiated thyroid gland carcinoma, metastatic nut carcinoma, metastatic thyroid gland anaplastic carcinoma, metastatic thyroid gland medullary carcinoma, refractory differentiated thyroid gland carcinoma, stage iii differentiated thyroid gland carcinoma ajcc v8, stage iii thyroid gland medullary carcinoma ajcc v8, stage iv differentiated thyroid gland carcinoma ajcc v8, stage iv thyroid gland medullary carcinoma ajcc v8, unresectable differentiated thyroid gland carcinoma, unresectable nut carcinoma, unresectable thyroid gland anaplastic carcinoma, unresectable thyroid gland medullary carcinoma